167 related articles for article (PubMed ID: 20727991)
1. Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy.
Das M; Sahoo SK
Acta Biomater; 2011 Jan; 7(1):355-69. PubMed ID: 20727991
[TBL] [Abstract][Full Text] [Related]
2. Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy.
Das M; Dilnawaz F; Sahoo SK
Nanomedicine (Lond); 2011 Apr; 6(3):489-507. PubMed ID: 21542687
[TBL] [Abstract][Full Text] [Related]
3. Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance.
Das M; Sahoo SK
PLoS One; 2012; 7(3):e32920. PubMed ID: 22470431
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional nanoparticle-EpCAM aptamer bioconjugates: a paradigm for targeted drug delivery and imaging in cancer therapy.
Das M; Duan W; Sahoo SK
Nanomedicine; 2015 Feb; 11(2):379-89. PubMed ID: 25240596
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
6. Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells.
Mitra M; Misra R; Harilal A; Sahoo SK; Krishnakumar S
Mol Vis; 2011; 17():2724-37. PubMed ID: 22065926
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticles loaded with Nutlin-3 display cytotoxicity towards p53(wild-type) JVM-2 but not towards p53(mutated) BJAB leukemic cells.
Voltan R; Secchiero P; Ruozi B; Caruso L; Forni F; Palomba M; Zauli G; Vandelli MA
Curr Med Chem; 2013; 20(21):2712-22. PubMed ID: 23627936
[TBL] [Abstract][Full Text] [Related]
8. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
[TBL] [Abstract][Full Text] [Related]
10. TRIAD1 Is a Novel Transcriptional Target of p53 and Regulates Nutlin-3a-Induced Cell Death.
Lee J; An S; Choi YM; Jung JH; Li L; Meng H; Dong Y; Ahn KJ; An IS; Bae S
J Cell Biochem; 2017 Jul; 118(7):1733-1740. PubMed ID: 27935098
[TBL] [Abstract][Full Text] [Related]
11. Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells.
Mitra M; Kandalam M; Rangasamy J; Shankar B; Maheswari UK; Swaminathan S; Krishnakumar S
Mol Vis; 2013; 19():1029-38. PubMed ID: 23687439
[TBL] [Abstract][Full Text] [Related]
12. Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells.
Shen H; Moran DM; Maki CG
Cancer Res; 2008 Oct; 68(20):8260-8. PubMed ID: 18922897
[TBL] [Abstract][Full Text] [Related]
13. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
Drakos E; Atsaves V; Schlette E; Li J; Papanastasi I; Rassidakis GZ; Medeiros LJ
Leukemia; 2009 Dec; 23(12):2290-9. PubMed ID: 19741726
[TBL] [Abstract][Full Text] [Related]
15. Nutlin-3a is a potential therapeutic for ewing sarcoma.
Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
[TBL] [Abstract][Full Text] [Related]
16. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
[TBL] [Abstract][Full Text] [Related]
17. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.
Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M
Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205
[TBL] [Abstract][Full Text] [Related]
18. Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells.
Shen H; Maki CG
J Biol Chem; 2010 Jul; 285(30):23105-14. PubMed ID: 20489208
[TBL] [Abstract][Full Text] [Related]
19. Safety and proof-of-concept efficacy of inhaled drug loaded nano- and immunonanoparticles in a c-Raf transgenic lung cancer model.
Karra N; Nassar T; Laenger F; Benita S; Borlak J
Curr Cancer Drug Targets; 2013 Jan; 13(1):11-29. PubMed ID: 23030233
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer.
Alibolandi M; Ramezani M; Abnous K; Sadeghi F; Atyabi F; Asouri M; Ahmadi AA; Hadizadeh F
J Control Release; 2015 Jul; 209():88-100. PubMed ID: 25912964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
